{"id":412868,"date":"2021-01-12T08:03:07","date_gmt":"2021-01-12T13:03:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412868"},"modified":"2021-01-12T08:03:07","modified_gmt":"2021-01-12T13:03:07","slug":"pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/","title":{"rendered":"Pliant Therapeutics Announces Appointment of  David Pyott to Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Jan.  12, 2021  (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. David Pyott, former Chairman and Chief Executive Officer of Allergan, to Pliant\u2019s Board of Directors.\u00a0\u00a0<\/p>\n<p align=\"left\">\u201cDavid is an accomplished international pharmaceutical executive whose extensive experience in building companies will be invaluable at this stage of Pliant\u2019s development,\u201d said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. \u201cIt is my great pleasure to welcome David to the Board and look forward to his insights as we advance and expand our clinical stage portfolio.\u201d<\/p>\n<p align=\"left\">Dr. Pyott joins the Pliant Board of Directors with more than 30 years of executive leadership and management experience within the global pharmaceutical industry. Dr. Pyott most recently served as Chairman and Chief Executive Offer of Allergan, where, over his 17-year tenure in this role, he transformed the company from a small eye care business with $1 billion in annual sales into a global specialty pharmaceutical and medical device company with 2014 annual sales of over $7 billion. Prior to Allergan, Dr. Pyott held the role of Head of the Novartis Nutrition Division and served as a member of the Executive Committee of Switzerland-based Novartis AG.<\/p>\n<p align=\"left\">\u201cI am excited to be joining the Pliant board and supporting an accomplished group of board members and a strong leadership team to help guide the company\u2019s mission of delivering innovative and potential transformative treatments to patients,\u201d said Dr. Pyott. \u201cI believe Pliant\u2019s novel approach has the potential to address the need for new treatments for fibrotic diseases.\u201d<\/p>\n<p align=\"left\">In addition to Pliant, Dr. Pyott currently serves as a member of the Board of Directors of Alnylam Pharmaceuticals and BioMarin Pharmaceutical, as Chairman of Bioniz Therapeutics, Inc., a private biotechnology company, and is a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health technology company. Dr. Pyott serves as Deputy Chairman of the Governing Board of the London Business School, President of the Ophthalmology Foundation, President of the Advisory Board of the American Academy of Ophthalmology and is also a Trustee of the California Institute of Technology.<\/p>\n<p align=\"left\">Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School.<\/p>\n<p align=\"left\">\n        <strong>About\u00a0Pliant Therapeutics, Inc.<br \/><\/strong>Pliant Therapeutics\u00a0is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant&#8217;s lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of a<sub>v<\/sub>\u00df<sub>6<\/sub>\u00a0and a<sub>v<\/sub>\u00df<sub>1<\/sub>\u00a0integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the\u00a0U.S. Food and Drug Administration\u00a0for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant&#8217;s second product candidate, PLN-1474, is a small-molecule selective inhibitor of a<sub>v<\/sub>\u00df<sub>1<\/sub>\u00a0for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about\u00a0Pliant Therapeutics, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7vaNNk_xM5WGyGdG-yLmN_fqO-poguUA1b2rhIkDowGxVUD2PpgaVWC7b6o3LZVoeewDvMHaL54KDpqzMrAqRQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.pliantrx.com<\/u><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n4IJYpF0qv6foEbSPipgTn-aycULCjtIn6_Cgc-FnGEnijSsnvBeMBjhhhou2RTZVnjRvwj0OXNSW6Cx-b62bA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Twitter<\/u><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DmcGGU40516HRoLMMcbkBhtXuT8LMtOMFE09Gpm5K52SjQgPFlHuqyPwjusSzBBvsodXBGYdnBzLUSGyFAo_ih34mDF35wsagIP90dZO1bq06CbxKbB37Zh6Z9QG4kh1\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>LinkedIn<\/u><\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p7flDIfkE-1sACfPz7AcBlLwN_oNk4IFCp1IkgAvhP5FuuClPNc3B25uXLraXICWf7ELDKlJyiqiiEpMvO1r-g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Facebook<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/> Christopher Keenan<br \/> Vice President, Investor Relations and Corporate Communications<br \/> Pliant Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VKt2v35Ehx3texQWK_F2_5YZ63rhKGHiJz0DNnpgDwU-AGxw0Ti6cJ4J2q9cSIboBQnIwBWDSCRoe6jFh8elzA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>ir@pliantrx.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/> Cambria Fuqua<br \/> Canale Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u7efrDv2WcqzzjYwTuC59oxiagthWeln0u__qbQ3Jf5QFOZp5TyALyU6oFLHumswDzh6zSwPSOvZHg7YW8ERL6E5svpHhtLhljNhjQPsN6IrMGtjf5fcPLvzICQTansU\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>cambria.fuqua@canalecomm.com<\/u><\/a><\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9WbMrPkD2vGwDB0-MWkom2tdz7qD07UJ0okWTU_GG5OVvryTyivFIMe9qP3Z1zQAgE6JklP91HCzX67Aab6cmKLx3QfZrnWZkujMuiY_IHbIB1XkHs9vEV_Z5bM2WQ2eM6AlkAhYeArynt2YQo8cpePch3p1O7cNl8F4Iks2GFXHZNLxJMxp9irHOJnzFWXYeHLKZ4AG5ZFmsMlrpAdL_8BIhpt64CXsHNY1FlcUFj1Ohky7oeZK-mKjKm8sY-rtufIaBRVGAar8SWQLhz2IJQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/95826a4d-80dc-482a-aab1-c8684bfa48e5<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3fc45187-5986-4cf0-be73-181b1cf6196c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. David Pyott, former Chairman and Chief Executive Officer of Allergan, to Pliant\u2019s Board of Directors.\u00a0\u00a0 \u201cDavid is an accomplished international pharmaceutical executive whose extensive experience in building companies will be invaluable at this stage of Pliant\u2019s development,\u201d said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. \u201cIt is my great pleasure to welcome David to the Board and look forward to his insights as we advance and expand our clinical stage portfolio.\u201d Dr. Pyott joins the Pliant Board of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pliant Therapeutics Announces Appointment of  David Pyott to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412868","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. David Pyott, former Chairman and Chief Executive Officer of Allergan, to Pliant\u2019s Board of Directors.\u00a0\u00a0 \u201cDavid is an accomplished international pharmaceutical executive whose extensive experience in building companies will be invaluable at this stage of Pliant\u2019s development,\u201d said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. \u201cIt is my great pleasure to welcome David to the Board and look forward to his insights as we advance and expand our clinical stage portfolio.\u201d Dr. Pyott joins the Pliant Board of &hellip; Continue reading &quot;Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-12T13:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors\",\"datePublished\":\"2021-01-12T13:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/\"},\"wordCount\":644,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/\",\"name\":\"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=\",\"datePublished\":\"2021-01-12T13:03:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. David Pyott, former Chairman and Chief Executive Officer of Allergan, to Pliant\u2019s Board of Directors.\u00a0\u00a0 \u201cDavid is an accomplished international pharmaceutical executive whose extensive experience in building companies will be invaluable at this stage of Pliant\u2019s development,\u201d said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. \u201cIt is my great pleasure to welcome David to the Board and look forward to his insights as we advance and expand our clinical stage portfolio.\u201d Dr. Pyott joins the Pliant Board of &hellip; Continue reading \"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-12T13:03:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors","datePublished":"2021-01-12T13:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/"},"wordCount":644,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/","name":"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=","datePublished":"2021-01-12T13:03:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE4MiMzOTE0NTIyIzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412868"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412868\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}